Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How to Approach Sustainability in Healthcare Design: Build for Impact

A proponent of lifelong learning, Daniel A. Huard is a sought‐after green building expert also recognized as the Godfather of sustainability. Huard is launching Build For Impact, aiming to build a platform to allow for collaboration with some of the best minds in the world who focus on green design and sustainability. Building has long been a part of…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

A proponent of lifelong learning, Daniel A. Huard is a sought‐after green building expert also recognized as the Godfather of sustainability. Huard is launching Build For Impact, aiming to build a platform to allow for collaboration with some of the best minds in the world who focus on green design and sustainability.

Building has long been a part of the human experience. It’s been a critical aspect in the evolution of life. Now construction and design are more than just about how it looks and how it works. The new horizon is focusing on sustainability, resilience, and material transparency. To lend expertise on the subject, architect Jane Rohde, Principal at JSR Associates, with a list of distinguished awards and certifications, joins Hthe show.

Sustainability is a buzzword in architecture, but what does it really mean right now? Rohde shared, “Sustainability isn’t a single attribute. It’s integrated together. Being in healthcare, I see this more prominently, the unintended consequences of not looking at performance.”

Alongside sustainability comes resiliency, which describes the ability of a building to prevent and recover from damage. “Resiliency now really ties into emergency preparedness. Looking at nursing homes hit hard by COVID or how hospitals on the Texas coast prepared for Hurricane Harvey. If design intention and operation intention are considered together, it’s a much better outcome,” Rohde commented. 

Another critical subject is material transparency. To be fully transparent is difficult for manufacturers and supply chains. It’s not just what the product is; it’s where it’s from and the conditions of that area.

“With material transparency, there are bigger questions that we don’t have answers to, regarding social responsibility. But the conversations are happening. What’s critical is not to look at it from a single attribute perspective. The better way may be from an exposure and risk perspective,” Rohde stated.

Listen To Previous Episodes of Build for Impact Right Here!

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512